Journal
NATURE MEDICINE
Volume 17, Issue 8, Pages 941-943Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2407
Keywords
-
Funding
- US National Institutes of Health [HD0433871, CA129045, CA40046, CA55727, GM089941, CA139278, CA58839, CA110836]
- US National Institutes of Health/National Institute of General Medical Sciences Pharmacogenomics of Anticancer Agents [U01GM61393, N01-PC-35139]
- US Army Medical Research and Materiel Command (Department of Defense) [PR054600]
- Department of Defense DAMD [17-097-1-7147]
- American Cancer Society-Illinois Division
- American Lebanese Syrian Associated Charities
- Leukemia Lymphoma Society [TR 6137-07, TR 6202-09]
- Breast Cancer Research Foundation
- Lymphoma Foundation
- Robert and Kate Niehaus Research Fund
- University of Chicago Cancer Center [P30 CA14599]
- Breast Cancer Specialized Program
- Cancer Research Foundation
- California Department of Health Services
Ask authors/readers for more resources
Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
